ACER
Acer Therapeutics Inc. [ACER] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ACER Stock Summary
In the News
ACER Financial details
Company Rating
Neutral
Market Cap
16.15M
Income
-60.92M
Revenue
371.79K
Book val./share
-1.95
Cash/share
0.02
Dividend
-
Dividend %
-
Employees
30
Optionable
No
Shortable
Yes
Earnings
20 Nov 2023
P/E
-0.27
Forward P/E
-
PEG
-0.02
P/S
43.43
P/B
-0.34
P/C
33.01
P/FCF
-0.41
Quick Ratio
0.01
Current Ratio
0.1
Debt / Equity
-0.38
LT Debt / Equity
-
-
-
EPS (TTM)
-2.85
EPS next Y
-
EPS next Q
-
EPS this Y
71.84%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-6.6%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
81.82%
-
-
-
-
SMA20
-2.41%
SMA50
-
SMA100
-
Inst Own
11.87%
Inst Trans
1%
ROA
-435%
ROE
197%
ROC
0.36%
Gross Margin
77%
Oper. Margin
-4576%
Profit Margin
-16386%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.55-4.56
52W High
-
52W Low
-
RSI
26.55
Rel Volume
0.24
Avg Volume
2.39M
Volume
574.68K
Perf Week
-18.51%
Perf Month
-
Perf Quarter
-
Perf Half Y
-18.19%
-
-
-
-
Beta
0.441
-
-
Volatility
0.06%, 0.04%
Prev Close
-17.95%
Price
0.6601
Change
-16.45%
ACER Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.05 | 0 | 0 | 0.09 | 0 | |
| Net income per share | -2.49 | -2.86 | -2.06 | -1.03 | -1.77 | |
| Operating cash flow per share | -1.94 | -2.92 | -1.53 | -0.01 | -1.92 | |
| Free cash flow per share | -1.95 | -2.94 | -1.53 | -0.01 | -1.93 | |
| Cash per share | 4.87 | 1.2 | 0.52 | 0.89 | 0.15 | |
| Book value per share | 5.27 | 1.82 | 0.74 | -0.12 | -1.06 | |
| Tangible book value per share | 4.36 | 1.05 | 0.05 | -0.66 | -1.55 | |
| Share holders equity per share | 5.27 | 1.82 | 0.74 | -0.12 | -1.06 | |
| Interest debt per share | 0 | 0.06 | 0.03 | 0.03 | 0.76 | |
| Market cap | 172.13M | 40.47M | 29.14M | 32.53M | 39.58M | |
| Enterprise value | 130.46M | 28.98M | 23.74M | 20.21M | 49.11M | |
| P/E ratio | -8.09 | -1.4 | -1.27 | -2.21 | -1.42 | |
| Price to sales ratio | 398.34 | 0 | 0 | 25.82 | 0 | |
| POCF ratio | -10.38 | -1.37 | -1.71 | -241.14 | -1.31 | |
| PFCF ratio | -10.32 | -1.36 | -1.71 | -171.35 | -1.3 | |
| P/B Ratio | 3.82 | 2.2 | 3.54 | -18.87 | -2.36 | |
| PTB ratio | 3.82 | 2.2 | 3.54 | -18.87 | -2.36 | |
| EV to sales | 301.9 | 0 | 0 | 16.04 | 0 | |
| Enterprise value over EBITDA | -6.12 | -0.97 | -1.05 | -1.26 | -1.98 | |
| EV to operating cash flow | -7.86 | -0.98 | -1.39 | -149.84 | -1.62 | |
| EV to free cash flow | -7.82 | -0.98 | -1.39 | -106.48 | -1.61 | |
| Earnings yield | -0.12 | -0.71 | -0.79 | -0.45 | -0.7 | |
| Free cash flow yield | -0.1 | -0.73 | -0.58 | -0.01 | -0.77 | |
| Debt to equity | 0 | 0.03 | 0.04 | -0.23 | -0.71 | |
| Debt to assets | 0 | 0.03 | 0.02 | 0.01 | 1.02 | |
| Net debt to EBITDA | 1.96 | 0.38 | 0.24 | 0.77 | -0.38 | |
| Current ratio | 7.66 | 4.65 | 1.05 | 0.96 | 0.19 | |
| Interest coverage | -22K | 0 | 0 | 0 | -242.67 | |
| Income quality | 0.78 | 1 | 0.74 | 0.01 | 1.15 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 21.43 | 0 | 0 | 8.49 | 0 | |
| Research and developement to revenue | 28.82 | 0 | 0 | 5.17 | 0 | |
| Intangibles to total assets | 0.15 | 0.36 | 0.52 | 0.21 | 0.66 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0 | 0.41 | 0.01 | |
| Capex to revenue | -0.22 | 0 | 0 | -0.04 | 0 | |
| Capex to depreciation | -3.45 | -3.07 | -0.15 | -0.77 | -2.59 | |
| Stock based compensation to revenue | 3.05 | 0 | 0 | 1.82 | 0 | |
| Graham number | 17.17 | 10.83 | 5.85 | 1.68 | 6.5 | |
| ROIC | -0.47 | -1.5 | -2.55 | 16.32 | 5.62 | |
| Return on tangible assets | -0.5 | -2.11 | -3.29 | -0.51 | -7.01 | |
| Graham Net | 4.22 | 0.89 | -0.06 | -1.47 | -1.65 | |
| Working capital | 37.17M | 10.12M | 295.48K | -1.02M | -15.44M | |
| Tangible asset value | 37.32M | 10.6M | 577.07K | -9.37M | -24.41M | |
| Net current asset value | 37.17M | 9.79M | 51.68K | -9.89M | -24.87M | |
| Invested capital | 0 | 0.03 | 0.04 | -0.23 | -0.71 | |
| Average receivables | 0 | 0 | 0 | 2.5M | 2.5M | |
| Average payables | 564.85K | 797.46K | 1.12M | 1.54M | 2.61M | |
| Average inventory | 0 | 0 | 0 | 547.11K | 547.11K | |
| Days sales outstanding | 0 | 0 | 0 | 1.45K | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0.25 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.47 | -1.57 | -2.78 | 8.55 | 1.66 | |
| Capex per share | -0.01 | -0.02 | 0 | 0 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0.02 | |
| Net income per share | -0.31 | -0.65 | -1.27 | -0.33 | -0.6 | |
| Operating cash flow per share | -0.56 | -0.48 | -0.43 | -0.23 | -0.65 | |
| Free cash flow per share | -0.57 | -0.49 | -0.43 | -0.23 | -0.65 | |
| Cash per share | 0.4 | 0.13 | 0.3 | 0.06 | 0.02 | |
| Book value per share | -0.76 | -0.97 | -1.24 | -1.36 | -1.95 | |
| Tangible book value per share | -1.23 | -1.41 | -1.6 | -1.67 | -2.26 | |
| Share holders equity per share | -0.76 | -0.97 | -1.24 | -1.36 | -1.95 | |
| Interest debt per share | 0.51 | 0.69 | 1.34 | 1.29 | 0.74 | |
| Market cap | 22.36M | 43.57M | 16.05M | 22.51M | 19.94M | |
| Enterprise value | 24.23M | 53.11M | 38.34M | 53.22M | 37.5M | |
| P/E ratio | -1.12 | -0.97 | -0.15 | -0.7 | -0.34 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 53.63 | |
| POCF ratio | -2.46 | -5.25 | -1.78 | -4.09 | -1.25 | |
| PFCF ratio | -2.46 | -5.17 | -1.78 | -4.09 | -1.25 | |
| P/B Ratio | -1.83 | -2.6 | -0.61 | -0.68 | -0.42 | |
| PTB ratio | -1.83 | -2.6 | -0.61 | -0.68 | -0.42 | |
| EV to sales | 0 | 0 | 0 | 0 | 100.85 | |
| Enterprise value over EBITDA | -4.36 | -39.33 | 7.05 | -47.19 | -2.91 | |
| EV to operating cash flow | -2.67 | -6.4 | -4.25 | -9.67 | -2.34 | |
| EV to free cash flow | -2.67 | -6.3 | -4.25 | -9.67 | -2.34 | |
| Earnings yield | -0.22 | -0.26 | -1.67 | -0.36 | -0.74 | |
| Free cash flow yield | -0.41 | -0.19 | -0.56 | -0.24 | -0.8 | |
| Debt to equity | -0.68 | -0.71 | -1.1 | -0.97 | -0.38 | |
| Debt to assets | 0.54 | 1.02 | 1.83 | 2.2 | 1.3 | |
| Net debt to EBITDA | -0.34 | -7.06 | 4.1 | -27.23 | -1.36 | |
| Current ratio | 0.35 | 0.19 | 0.2 | 0.16 | 0.1 | |
| Interest coverage | -269.62 | -64.18 | -18.93 | 6.71 | 96.71 | |
| Income quality | 1.81 | 0.88 | 0.55 | 0.68 | 0.98 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 4.09 | |
| Intangibles to total assets | 0.5 | 0.66 | 0.49 | 0.52 | 0.55 | |
| Capex to operating cash flow | 0 | 0.02 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.35 | -10.21 | -0.2 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.77 | |
| Graham number | 2.3 | 3.75 | 5.95 | 3.18 | 5.14 | |
| ROIC | 1.38 | 1.36 | 3.32 | 8.21 | 0.44 | |
| Return on tangible assets | -0.65 | -2.83 | -3.35 | -1.16 | -2.32 | |
| Graham Net | -1.31 | -1.5 | -1.64 | -1.78 | -2.39 | |
| Working capital | -13.49M | -15.44M | -30.39M | -36.68M | -55.53M | |
| Tangible asset value | -19.85M | -24.41M | -33.76M | -40.89M | -55.39M | |
| Net current asset value | -20.23M | -24.87M | -34.18M | -41.14M | -55.61M | |
| Invested capital | -0.68 | -0.71 | -1.1 | -0.97 | -0.38 | |
| Average receivables | 0 | 0 | 400.39K | 692.06K | 291.67K | |
| Average payables | 4.09M | 4.25M | 2.71M | 3.66M | 6.36M | |
| Average inventory | 0 | 0 | 206.02K | 2.51M | 4.9M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 7.53K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 5.59K | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0.01 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0.02 | |
| ROE | 0.41 | 0.67 | 1.03 | 0.24 | 0.31 | |
| Capex per share | 0 | -0.01 | 0 | 0 | 0 |
ACER Frequently Asked Questions
What is Acer Therapeutics Inc. stock symbol ?
Acer Therapeutics Inc. is a US stock , located in Newton of Ma and trading under the symbol ACER
What is Acer Therapeutics Inc. stock quote today ?
Acer Therapeutics Inc. stock price is $0.6601 today.
Is Acer Therapeutics Inc. stock public?
Yes, Acer Therapeutics Inc. is a publicly traded company.
Company Profile
- Volume Average 2.39M
- Market Capitalization 16.15M
- Employee 30
- CEO Mr. Christopher Schelling
- Headquarters Newton,MA,US
- IPO Date 2004-04-14
-
Website
https://www.acertx.com 
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
